Rpg Life Sciences Share Price
Sector: Biotechnology & Drugs
2409.00 -22.98 (-0.94%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2387.00
Today’s High
2463.60
52 Week Low
1454.60
52 Week High
2971.79
2414.50 -9.70 (-0.40%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2384.00
Today’s High
2443.30
52 Week Low
1526.53
52 Week High
2970.05
Key Metrics
- Market Cap (In Cr) 3964.78
- Beta 0.37
- Div. Yield (%) 0.83
- P/B 7.49
- TTM P/E 20.56
- Sector P/E 22.43
- D/E 0
- Open Price 2463.6
- Prev Close 2431.98
Rpg Life Sciences Analysis
Price Analysis
-
1 Week0.98%
-
3 Months5.41%
-
6 Month13.46%
-
YTD10.09%
-
1 Year49.45%
Risk Meter
- 50% Low risk
- 50% Moderate risk
- 50% Balanced Risk
- 50% High risk
- 50% Extreme risk
Rpg Life Sciences News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
2 min read . 06 Jan 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends 5 shares to buy today
2 min read . 09 Aug 2024Multibagger pharma stock up over 230% in 3 years, Board declares 150% dividend
3 min read . 29 Apr 2023Rpg Life Sciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 653.43
- Selling/ General/ Admin Expenses Total
- 247.06
- Depreciation/ Amortization
- 21.43
- Other Operating Expenses Total
- 5.14
- Total Operating Expense
- 432.61
- Operating Income
- 220.82
- Net Income Before Taxes
- 232.88
- Net Income
- 183.24
- Diluted Normalized EPS
- 70.92
- Period
- 2025
- Total Assets
- 657.81
- Total Liabilities
- 127.28
- Total Equity
- 530.53
- Tangible Book Valueper Share Common Eq
- 307.01
- Period
- 2025
- Cashfrom Operating Activities
- 77.86
- Cashfrom Investing Activities
- -41.8
- Cashfrom Financing Activities
- -27.08
- Net Changein Cash
- 8.98
- Period
- 2024
- Total Revenue
- 582.05
- Selling/ General/ Admin Expenses Total
- 239.43
- Depreciation/ Amortization
- 17.07
- Other Operating Expenses Total
- 5.91
- Total Operating Expense
- 470.97
- Operating Income
- 111.08
- Net Income Before Taxes
- 117.84
- Net Income
- 87.66
- Diluted Normalized EPS
- 53
- Period
- 2024
- Total Assets
- 512.87
- Total Liabilities
- 138.02
- Total Equity
- 374.85
- Tangible Book Valueper Share Common Eq
- 209.7
- Period
- 2024
- Cashfrom Operating Activities
- 94.36
- Cashfrom Investing Activities
- -79.15
- Cashfrom Financing Activities
- -20.31
- Net Changein Cash
- -5.1
- Period
- 2023
- Total Revenue
- 512.81
- Selling/ General/ Admin Expenses Total
- 224.82
- Depreciation/ Amortization
- 15.5
- Total Operating Expense
- 424.84
- Operating Income
- 87.97
- Net Income Before Taxes
- 91.68
- Net Income
- 67.64
- Diluted Normalized EPS
- 41.25
- Period
- 2023
- Total Assets
- 419.35
- Total Liabilities
- 111.75
- Total Equity
- 307.6
- Tangible Book Valueper Share Common Eq
- 165.79
- Period
- 2023
- Cashfrom Operating Activities
- 90.81
- Cashfrom Investing Activities
- -105.81
- Cashfrom Financing Activities
- -17.12
- Net Changein Cash
- -32.12
- Period
- 2022
- Total Revenue
- 440.16
- Selling/ General/ Admin Expenses Total
- 187.1
- Depreciation/ Amortization
- 15.66
- Other Operating Expenses Total
- 3.8
- Total Operating Expense
- 369.46
- Operating Income
- 70.7
- Net Income Before Taxes
- 73.17
- Net Income
- 51.48
- Diluted Normalized EPS
- 31.13
- Period
- 2022
- Total Assets
- 344.61
- Total Liabilities
- 88.84
- Total Equity
- 255.77
- Tangible Book Valueper Share Common Eq
- 133.68
- Period
- 2022
- Cashfrom Operating Activities
- 64.75
- Cashfrom Investing Activities
- -34.66
- Cashfrom Financing Activities
- -13.51
- Net Changein Cash
- 16.58
- Period
- 2021
- Total Revenue
- 389.14
- Selling/ General/ Admin Expenses Total
- 158.19
- Depreciation/ Amortization
- 16.47
- Other Operating Expenses Total
- 12.1
- Total Operating Expense
- 335.67
- Operating Income
- 53.47
- Net Income Before Taxes
- 53.58
- Net Income
- 40
- Diluted Normalized EPS
- 24.19
- Period
- 2021
- Total Assets
- 303.39
- Total Liabilities
- 86.94
- Total Equity
- 216.45
- Tangible Book Valueper Share Common Eq
- 108.42
- Period
- 2021
- Cashfrom Operating Activities
- 58.27
- Cashfrom Investing Activities
- -7.96
- Cashfrom Financing Activities
- -10.49
- Net Changein Cash
- 39.82
- Period
- 2020
- Total Revenue
- 375.57
- Selling/ General/ Admin Expenses Total
- 160.89
- Depreciation/ Amortization
- 16.36
- Other Operating Expenses Total
- 9.2
- Total Operating Expense
- 337.99
- Operating Income
- 37.58
- Net Income Before Taxes
- 36.45
- Net Income
- 29.01
- Diluted Normalized EPS
- 20.15
- Period
- 2020
- Total Assets
- 266.73
- Total Liabilities
- 90.16
- Total Equity
- 176.57
- Tangible Book Valueper Share Common Eq
- 81.44
- Period
- 2020
- Cashfrom Operating Activities
- 50.17
- Cashfrom Investing Activities
- -10.7
- Cashfrom Financing Activities
- -39.3
- Net Changein Cash
- 0.17
- Period
- 2025-03-31
- Total Revenue
- 143.09
- Selling/ General/ Admin Expenses Total
- 31.6
- Depreciation/ Amortization
- 5.37
- Other Operating Expenses Total
- 37.28
- Total Operating Expense
- 13.07
- Operating Income
- 130.02
- Net Income Before Taxes
- 134.9
- Net Income
- 117.35
- Diluted Normalized EPS
- 13.15
- Period
- 2025-03-31
- Total Assets
- 657.81
- Total Liabilities
- 127.28
- Total Equity
- 530.53
- Tangible Book Valueper Share Common Eq
- 307.01
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 77.86
- Cashfrom Investing Activities
- -41.8
- Cashfrom Financing Activities
- -27.08
- Net Changein Cash
- 8.98
- Period
- 2024-12-31
- Total Revenue
- 172.71
- Selling/ General/ Admin Expenses Total
- 28.71
- Depreciation/ Amortization
- 5.46
- Other Operating Expenses Total
- 38.73
- Total Operating Expense
- 129.01
- Operating Income
- 43.7
- Net Income Before Taxes
- 46.89
- Net Income
- 34.93
- Diluted Normalized EPS
- 21.12
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 172.21
- Selling/ General/ Admin Expenses Total
- 33.09
- Depreciation/ Amortization
- 5.31
- Other Operating Expenses Total
- 39.02
- Total Operating Expense
- 158.89
- Operating Income
- 13.32
- Net Income Before Taxes
- 15.09
- Net Income
- 4.2
- Diluted Normalized EPS
- 13.27
- Period
- 2024-09-30
- Total Assets
- 554.37
- Total Liabilities
- 174.99
- Total Equity
- 379.38
- Tangible Book Valueper Share Common Eq
- 213.84
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 46.33
- Cashfrom Investing Activities
- -21.99
- Cashfrom Financing Activities
- -26.78
- Net Changein Cash
- -2.44
- Period
- 2024-06-30
- Total Revenue
- 165.42
- Selling/ General/ Admin Expenses Total
- 32.74
- Depreciation/ Amortization
- 5.29
- Other Operating Expenses Total
- 38.6
- Total Operating Expense
- 131.64
- Operating Income
- 33.78
- Net Income Before Taxes
- 36
- Net Income
- 26.76
- Diluted Normalized EPS
- 16.18
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 126.99
- Selling/ General/ Admin Expenses Total
- 34.78
- Depreciation/ Amortization
- 4.49
- Other Operating Expenses Total
- 30.05
- Total Operating Expense
- 110.76
- Operating Income
- 16.23
- Net Income Before Taxes
- 17.74
- Net Income
- 13.24
- Diluted Normalized EPS
- 8
- Period
- 2024-03-31
- Total Assets
- 512.87
- Total Liabilities
- 138.02
- Total Equity
- 374.85
- Tangible Book Valueper Share Common Eq
- 209.7
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 94.36
- Cashfrom Investing Activities
- -79.15
- Cashfrom Financing Activities
- -20.31
- Net Changein Cash
- -5.1
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Rpg Life Sciences Technical
Moving Average
SMA
- 5 Day2412.07
- 10 Day2367.37
- 20 Day2269.35
- 50 Day2197.91
- 100 Day2224.77
- 300 Day2269.74
Rpg Life Sciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Hikal
- 361.45
- 1.7
- 0.47
- 464.5
- 304.25
- 4453.61
- Aarti Drugs
- 452.9
- 7.45
- 1.67
- 634.9
- 312.5
- 4133.62
- Rpg Life Sciences
- 2409
- -22.98
- -0.94
- 2971.79
- 1454.6
- 3964.78
- Dishman Carbogen Amcis
- 249.45
- 3.9
- 1.59
- 307.8
- 155
- 3870.76
- Advanced Enzyme Technologies
- 329
- 4.2
- 1.29
- 571.15
- 257.85
- 3678.62
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Hikal
- 88.38
- 3.51
- 9.93
- 5.71
- Aarti Drugs
- 24.27
- 2.97
- 18.24
- 8.08
- Rpg Life Sciences
- 34.24
- 7.57
- 28.51
- 16.68
- Dishman Carbogen Amcis
- 223.72
- 0.66
- -1.15
- -2.77
- Advanced Enzyme Technologies
- 27.72
- 2.56
- 11
- 22.95
Rpg Life Sciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-Apr-25
- Audited Results & Final Dividend
- 24-Jan-25
- Quarterly Results
- 07-Nov-24
- Quarterly Results
- 19-Jul-24
- Quarterly Results
- 30-Apr-24
- Audited Results & Final Dividend
- 01-Feb-24
- Quarterly Results
- 18-Oct-23
- Quarterly Results
- 28-Jul-23
- Quarterly Results
- 28-Apr-23
- Audited Results & Final Dividend
- 01-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 16-Nov-24
- 15-Oct-24
- POM
- 16-Jul-24
- 11-Jun-24
- AGM
- 09-Mar-24
- 07-Feb-24
- POM
- 04-Aug-23
- 28-Apr-23
- AGM
- 29-Jul-22
- 04-Jul-22
- AGM
- 31-Aug-21
- 09-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 30-Apr-25
- -
- -
- 4
- 29-Apr-25
- -
- -
- 20
- 30-Apr-24
- 28-Jun-24
- 28-Jun-24
- 16
- 28-Apr-23
- 21-Jul-23
- 21-Jul-23
- 12
- 29-Apr-22
- 15-Jul-22
- 14-Jul-22
- 9.6
- 30-Apr-21
- 17-Aug-21
- 13-Aug-21
- 7.2


